Results 21 to 30 of about 1,632,256 (263)

TRIP - T cell receptor/immunoglobulin profiler

BMC Bioinformatics, 2020
Background Antigen receptors are characterized by an extreme diversity of specificities, which poses major computational and analytical challenges, particularly in the era of high-throughput immunoprofiling by next generation sequencing (NGS). The T cell
Maria Th. Kotouza, Katerina Gemenetzi, Chrysi Galigalidou, Elisavet Vlachonikola, Nikolaos Pechlivanis, Andreas Agathangelidis, Raphael Sandaltzopoulos, Pericles A. Mitkas, Kostas Stamatopoulos, Anastasia Chatzidimitriou, Fotis E. Psomopoulos, on behalf of the Hellenic Precision Medicine Network in Oncology   +11 more
doaj   +1 more source

Chimeric antigen receptor natural killer cell therapy for solid tumors: mechanisms, clinical progress, and strategies to overcome the tumor microenvironment

Experimental Biology and Medicine
Natural killer (NK) cells represent a fundamental component of the innate immune system, endowed with the ability to identify and eradicate virus-infected and malignant cells.
Yu Xiang, Yu Xiang, Yu Xiang, Yu Xiang, Yu Xiang, Jiayi Dong, Jiayi Dong, Jiayi Dong, Jiayi Dong, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Size Chen, Size Chen, Size Chen, Size Chen, Size Chen   +18 more
doaj   +1 more source

Core Fucosylation of the T Cell Receptor Is Required for T Cell Activation

Frontiers in Immunology, 2018
CD4+ T cell activation promotes the pathogenic process of systemic lupus erythematosus (SLE). T cell receptor (TCR) complex are highly core fucosylated glycoproteins, which play important roles in T cell activation.
Wei Liang, Shanshan Mao, Shijie Sun, Ming Li, Zhi Li, Rui Yu, Tonghui Ma, Jianguo Gu, Jianing Zhang, Naoyuki Taniguchi, Wenzhe Li   +10 more
doaj   +1 more source

Generalizable design parameters for soluble T cell receptor-based T cell engagers

Journal for ImmunoTherapy of Cancer, 2022
While most biological and cellular immunotherapies recognize extracellular targets, T cell receptor (TCR) therapeutics are unique in their ability to recognize the much larger pool of intracellular antigens found on virus-infected or cancerous cells ...
Flora Huang, Arlene Sereno, Karen J Froning, Stephen J Demarest   +3 more
doaj   +1 more source

A Quality Improvement Initiative to Standardize Pneumocystis jirovecii Pneumonia Prophylaxis in Pediatric Patients With Solid Tumors

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Pediatric patients with extracranial solid tumors (ST) receiving chemotherapy are at an increased risk for Pneumocystis jirovecii pneumonia (PJP). However, evidence guiding prophylaxis practices in this population is limited. A PJP‐related fatality at our institution highlighted inconsistent prescribing approaches and concerns about
Kriti Kumar, Denise M. Connolly, Ellen Kellington, Elyse Zelunka, Karla Kerrigan, Furqan Shaikh, Paul C. Nathan, Meredith S. Irwin, Sarah Cohen‐Gogo   +8 more
wiley   +1 more source

Pazopanib Combined With Vincristine and Irinotecan in Relapsed Wilms Tumor: Encouraging Outcomes in a Heavily Pretreated Pediatric Cohort

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background While Wilms tumor (WT) typically has a favorable prognosis, relapsed cases—especially those with high‐risk histology—remain therapeutically challenging after intensive frontline therapy. The combination of vincristine and irinotecan has demonstrated activity in pediatric solid tumors, and pazopanib, a multi‐targeted tyrosine kinase ...
Maria Debora De Pasquale, Alessandro Crocoli, Giuseppe Maria Milano, Pierluigi Di Paolo, Francesca Diomedi Camassei, Ida Russo, Annalisa Serra   +6 more
wiley   +1 more source

Potential Early Risk Biomarkers for Reduced Forced Expiratory Volume in Children Post‐Hematopoietic Cell Transplantation

Pediatric Blood &Cancer, EarlyView.
ABSTRACT We sought to identify potential early risk biomarkers for lung disease in children post‐allogeneic HCT. Patients with pulmonary function tests 3 months post‐transplant and plasma samples between days 7 and 14 post‐HCT were included. Six of 27 subjects enrolled had reduced forced expiratory volume 1 (FEV1) z scores.
Isabella S. Small, Pi Chun Cheng, April L. Rahrig, Courtney M. Rowan   +3 more
wiley   +1 more source

In-depth analysis of the safety of CAR-T cell therapy for solid tumors

Frontiers in Immunology
In recent years, the rapid progress in oncology, immunology, and molecular biology has dramatically advanced cancer immunotherapy, particularly CAR-T cell therapy.
Jiayi Dong, Jiayi Dong, Jiayi Dong, Jiayi Dong, Jiexiong Wu, Ye Jin, Ye Jin, Ye Jin, Ye Jin, Ye Jin, Zhu Zheng, Zhu Zheng, Zhu Zheng, Zhu Zheng, Zhu Zheng, Ting Su, Ting Su, Ting Su, Ting Su, Ting Su, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Jiaxin Bei, Jiaxin Bei, Jiaxin Bei, Jiaxin Bei, Size Chen, Size Chen, Size Chen, Size Chen, Size Chen   +33 more
doaj   +1 more source

CCDC134 facilitates T cell activation through the regulation of early T cell receptor signaling

Frontiers in Immunology, 2023
Modulation of surface T cell antigen receptor (TCR) expression is crucial for proper T cell development and maintenance of mature T cell function at steady state and upon stimulation.
Tianzhuo Zhang, Qianwen Shi, Huining Gu, Biaoyi Yu, Sha Yin, Sha Yin, Qing Ge, Xiaoning Mo, Xiaofeng Liu, Jing Huang   +9 more
doaj   +1 more source

Personalizing the Pediatric Hematology/Oncology Fellowship: Adapting Training for the Next Generation

Pediatric Blood &Cancer, EarlyView.
ABSTRACT The pediatric hematology‐oncology fellowship training curriculum has not substantially changed since its inception. The first year of training is clinically focused, and the second and third years are devoted to scholarship. However, this current structure leaves many fellows less competitive in the current job market, resulting in ...
Scott C. Borinstein, Melissa J. Rose, Scott Moerdler, Richard Ho   +3 more
wiley   +1 more source